Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis

心房颤动 医学 透析 心脏病学 内科学 重症监护医学
作者
Ziv Harel,Brendan Smyth,Sunil V. Badve,Daniel Blum,William Beaubien‐Souligny,Samuel A. Silver,Edward G. Clark,Rita S. Suri,Thomas A. Mavrakanas,Joanna Sasal,Bhanu Prasad,John W. Eikelboom,Karthik Tennankore,Claudio Rigatto,Ivana Prce,François Madore,Fabrice Mac‐Way,Andrew Steele,Yangmin Zeng,Michelle Sholzberg,Paul Dorian,Andrew T. Yan,Manish M. Sood,David J. Gladstone,Chia‐Lin Tseng,Abhijat Kitchlu,Michael Walsh,Danny Sapir,Matthew J. Oliver,Murali Krishnan,Mercedeh Kiaii,Nikki Wong,Sradha Kotwal,Marissa Batisstella,Rey Acedillo,Charmaine E. Lok,M. Lynn Weir,Ron Wald
出处
期刊:Journal of The American Society of Nephrology
标识
DOI:10.1681/asn.0000000000000495
摘要

Background: Atrial fibrillation is common in individuals receiving dialysis. The role of oral anticoagulation in this population is uncertain given its exclusion from previous seminal clinical trials. Our objective was to determine the feasibility of performing a large definitive trial to establish the optimal anticoagulation strategy in individuals with atrial fibrillation receiving dialysis. Methods: The SAFE-D trial was a parallel-group, open-label, allocation-concealed, pilot randomized control trial that took place at 28 centres in Canada and Australia. The trial included adults (≥18 y) undergoing dialysis with a history of non-valvular atrial fibrillation who met the CHADS-65 criteria. Participants were randomized 1:1:1 to receive dose-adjusted warfarin, apixaban 5 mg twice daily, or no oral anticoagulation and followed for 26 weeks. The primary outcomes evaluated the following measures of feasibility: a) recruitment of the target population within 2 years from the start of the trial; and b) adherence of >80% of randomized patients to the allocated treatment strategy at the conclusion of follow-up. Secondary outcomes included stroke and bleeding. Results: From December 2019 through June 2022, 151 patients were enrolled and randomized to apixaban (n =51), warfarin (n=52) or no oral anticoagulation (n=48). Allowing for pauses related to the COVID pandemic, recruitment was completed in 30 months, and 123 (83%) of participants completed follow-up in their allocated treatment arm. There was one adjudicated stroke event. Eight participants had a major bleeding event (4 warfarin, 2 apixaban, 2 no oral anticoagulation). Death occurred in 15 participants (9 warfarin, 2 apixaban, 4 no oral anticoagulation). Time in the therapeutic range for warfarin recipients was 58% (IQR 47%-70%). Conclusions: We have demonstrated the feasibility of recruitment and adherence in a trial that compared different anticoagulation strategies in patients with atrial fibrillation receiving dialysis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大人发布了新的文献求助10
刚刚
望都发布了新的文献求助10
刚刚
且从容完成签到,获得积分10
1秒前
青青河边草完成签到,获得积分10
1秒前
在水一方应助深情芷采纳,获得10
2秒前
3秒前
orixero应助小戴采纳,获得10
3秒前
xiaoyaoyou351完成签到,获得积分10
4秒前
quan完成签到,获得积分10
4秒前
aqiu完成签到,获得积分10
5秒前
Ken921319005完成签到,获得积分10
6秒前
7秒前
jby发布了新的文献求助10
8秒前
福福关注了科研通微信公众号
8秒前
9秒前
醉仙关注了科研通微信公众号
10秒前
SciGPT应助123采纳,获得10
11秒前
昂叔的头发丝儿完成签到,获得积分10
11秒前
12秒前
羽雨完成签到,获得积分10
12秒前
完美世界应助仁爱晓瑶采纳,获得10
12秒前
12秒前
定西发布了新的文献求助10
13秒前
13秒前
kento应助Ken921319005采纳,获得100
14秒前
程大学发布了新的文献求助10
14秒前
14秒前
羽雨发布了新的文献求助10
15秒前
塵亦发布了新的文献求助10
16秒前
18秒前
18秒前
科研通AI2S应助zxvcbnm采纳,获得10
19秒前
月下荷花完成签到,获得积分10
19秒前
可爱语堂发布了新的文献求助10
19秒前
香蕉觅云应助踏实语蓉采纳,获得10
20秒前
绝版的飞完成签到,获得积分20
20秒前
科研小白完成签到 ,获得积分10
20秒前
塵亦完成签到,获得积分10
21秒前
21秒前
22秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3135145
求助须知:如何正确求助?哪些是违规求助? 2786103
关于积分的说明 7775648
捐赠科研通 2441991
什么是DOI,文献DOI怎么找? 1298332
科研通“疑难数据库(出版商)”最低求助积分说明 625112
版权声明 600845